title: Tissue IGFBP-3 proteolysis: contrasting pathophysiology to that in the circulation.
abstract: Endogenous IGFBP-3 has been examined in the circulation and in four different extravascular fluids in normal healthy adults and in patients with psoriasis or arthritis. In all of these cases there was no apparent increase of IGFBP-3 protease activity in the circulation. In contrast, endogenous IGFBP-3 from normal skin interstititial fluid and synovial fluid from healthy adults was found to be predominantly in the 29 kDa proteolytically modified form. This indicated that in these extravascular fluids in normal healthy adults a protease was active which was similar, if not identical, to that found in the circulation in pregnancy and other conditions. This was confirmed by the fragmentation of recombinant IGFBP-3 when incubated with these fluids. When the skin interstitial fluid or synovial fluid were taken from abnormal tissues (psoriasis in the former and osteoarthritis or rheumatoid arthritis in the latter) there was a considerable reduction in the amount of endogenous IGFBP-3 in the 'clipped' form and a reduction in the protease activity. In psoriatic lesions, this reduction in IGFBP-3 protease activity was shown to be due to the presence of an inhibitor in the interstitial fluid but not in the circulation. In both peritoneal and follicular fluid, the ratio of intact to fragmented IGFBP-3 appeared to relate to the oestrogen status. In peritoneal fluid there was a decrease in intact IGFBP-3 during the late proliferative/early secretory phase of the endometrial cycle. In the ovary there was an increase in the amount of fragmented IGFBP-3 in the follicular fluid from the dominant follicle in comparison with atretic follicles from the same ovary. There is normally little proteo-lysis of IGFBP-3 in the circulation but this increases in many conditions where there is increased metabolic activity. The same enzyme(s) appear to be active in many extravascular fluids but under very different regulation. The activity in these extravascular fluids is normally high but can be decreased with local tissue inflammation; this decrease appears to be mediated by the induction of a local inhibitor.
authors.affiliation: University Department of Medicine, Bristol Royal Infirmary, Bristol, U.K.
authors.forename: S C
authors.initials: SC
authors.lastname: Hughes
authors.forename: S
authors.initials: S
authors.lastname: Xu
authors.forename: J
authors.initials: J
authors.lastname: Fernihough
authors.forename: A
authors.initials: A
authors.lastname: Hampton
authors.forename: H D
authors.initials: HD
authors.lastname: Mason
authors.forename: S
authors.initials: S
authors.lastname: Franks
authors.forename: J
authors.initials: J
authors.lastname: van der Stappen
authors.forename: M J
authors.initials: MJ
authors.lastname: Donnelly
authors.forename: J M
authors.initials: JM
authors.lastname: Holly
mesh_terms: D000328:Adult; D001172:Arthritis, Rheumatoid / Q000201:enzymology; D001202:Ascitic Fluid / Q000201:enzymology; D015153:Blotting, Western; D005260:Female; D015571:Follicular Fluid / Q000201:enzymology; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood / Q000378:metabolism*; D010003:Osteoarthritis / Q000201:enzymology; D011565:Psoriasis / Q000201:enzymology; D012867:Skin / Q000201:enzymology; D013582:Synovial Fluid / Q000201:enzymology
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3